These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pentostatin: impact on outcome in hairy cell leukemia. Grever MR Hematol Oncol Clin North Am; 2006 Oct; 20(5):1099-108. PubMed ID: 16990110 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Else M; Dearden CE; Catovsky D Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049 [TBL] [Abstract][Full Text] [Related]
8. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889 [TBL] [Abstract][Full Text] [Related]
9. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia. Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592 [No Abstract] [Full Text] [Related]
10. Hairy cell leukemia: treatment successes in the past 25 years. Golomb HM J Clin Oncol; 2008 Jun; 26(16):2607-9. PubMed ID: 18509168 [No Abstract] [Full Text] [Related]
11. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of hairy cell leukemia with cladribine]. Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550 [TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to purine analogs in hairy cell leukemia. Kraut EH Ann Intern Med; 1994 Feb; 120(3):247-8. PubMed ID: 7506014 [No Abstract] [Full Text] [Related]
14. Hairy cell leukemia: update and current therapeutic approach. Salam L; Abdel-Wahab O Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757 [TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066 [TBL] [Abstract][Full Text] [Related]
16. Cladribine in the treatment of hairy-cell leukaemia. Goodman GR; Beutler E; Saven A Best Pract Res Clin Haematol; 2003 Mar; 16(1):101-16. PubMed ID: 12670469 [TBL] [Abstract][Full Text] [Related]
17. Treatment of hairy-cell leukemia: current views. Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384 [TBL] [Abstract][Full Text] [Related]
18. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Rai KR Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325 [TBL] [Abstract][Full Text] [Related]
19. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Dasanu CA; Alexandrescu DT Expert Opin Pharmacother; 2010 Jan; 11(1):41-50. PubMed ID: 20001428 [TBL] [Abstract][Full Text] [Related]
20. Phase II trials of pentostatin (Nipent) in hairy cell leukemia. Kraut EH Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]